We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.15% | 97.65 | 1,190 | 13:37:34 |
From May 2022 to May 2024
By Cecilia Butini
Shares in Swiss pharma major Novartis AG gained in early trading on Monday after the company reported positive trial data for its breast-cancer treatment Kisqali, which analysts said were eagerly awaited.
At 0718 GMT, shares traded 5.6% higher at CHF80.67.
Novartis said that its drug Kisqali has met the trial's primary endpoint during an interim analysis, showing a clinically meaningful benefit in a population of patients with early breast cancer. The data readout had been "eagerly awaited," analysts at Jefferies said in a note.
The analysts said that this could represent a $6 billion opportunity as it implies upside on earnings per share of at least 2% to 4%, and of 2% to 3% on net present value. Consensus on earnings per share is expected to be lifted by 3% to 6%, according to Jefferies.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 27, 2023 03:42 ET (07:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
